EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic (IVD) technologies to the healthcare industry, announced today that its proprietary hydrophilic technology is being used on Medtronic’s U.S. Food and Drug Administration (FDA) approved Resolute Integrity™ Drug-Eluting Stent (DES) delivery system for the treatment of coronary artery disease (CAD).
